AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer.

CONCLUSION: Outcomes of CRPC patients are reported to be highly variable as consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design. PMID: 29173173 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29173173?dopt=Abstract

Source: Current Cancer Drug Targets - November 22, 2017 Category: Cancer & Oncology Authors: Salvi S, Conteduca V, Lolli C, Testoni S, Casadio V, Zaccheroni A, Rossi L, Burgio SL, Menna C, Schepisi G, De Giorgi U Tags: Curr Cancer Drug Targets Source Type: research